Overview
Spherix’s coverage of the inflammatory bowel disease market monitors the evolving landscape of ulcerative colitis and Crohn’s disease management with advanced therapies. We specifically track how new therapies influence changes in gastroenterologists’ attitudes and ultimately treatment decision-making.
Services Available
Trending market evolution
-
Crohn's Disease (US)
-
Crohn's Disease (EU)
-
Ulcerative Colitis (US)
-
Ulcerative Colitis (EU)
Service Info
RealTime Dynamix™ is an independent service providing strategic guidance through quarterly or semiannual reports, which include market trending and a fresh infusion of event-driven and variable content with each wave. The reports provide an unbiased view of the competitive landscape within rapidly evolving specialty markets, fueled by robust HCP primary research and our in-house team of experts.
Methodology: Insights are based on data collected from an online survey of respondents recruited from the Spherix Network, a proprietary group of specialty physicians in clinical practice meeting quality screening criteria.
Sample Size and Frequency
US: quarterly report (n=100-200 respondents)
EU5: semiannual report (n=250 respondents)
Canada: semiannual report (n=50 respondents)
Exploring the patient journey
-
Biologic/Small Molecule New Starts in IBD (US)
-
Biologic/Small Molecule Switching in IBD (US)
-
Biologic/Small Molecule Switching in IBD (EU)
Service Info
RealWorld Dynamix™ is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits. Insights reveal the “why” behind treatment decisions, include year over year trending to quantify key aspects of market evolution, and integrate specialists’ attitudinal & demographic data to highlight differences between stated and actual treatment patterns.
Report Methodology: Insights are based on patient level data gathered through collaboration with specialty physicians who provide details on clinical and non-clinical patient demographics, along with their rationale for treatment choices.
Sample Size and Frequency
US: annual patient chart audit (n=1,000 charts, n=200 physicians)
EU5: annual patient chart audit (n=1,250 charts, n=250 physicians)
Benchmarking new brand performance
-
Etrasimod (Arena) in Ulcerative Colitis (US)*
-
Mirikizumab (Eli Lilly) in Ulcerative Colitis (US)*
-
Rinvoq (AbbVie) in Ulcerative Colitis (US)
-
Skyrizi (AbbVie) in Crohn’s Disease (US)
-
Zeposia (BMS) in Ulcerative Colitis (US)
*Pending approvals and launch
Service Info
Launch Dynamix™ is an independent service providing monthly benchmarking of newly launched products for the first eighteen months of commercial availability, augmented by a quarterly deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand.
Methodology: Insights are based on analyses of quantitative data collected from an online survey of physicians “in the trenches” recruited from the Spherix Network, as well as qualitative interviews conducted with a subset of survey respondents.
Sample Size and Frequency
Monthly KPI benchmarking (n=75 physicians)
Quarterly report (n=75 physicians)
Quarterly qualitative interviews (n=8 physicians)
Gauging impact of disruptive events
-
Gastroenterology Biosimilars Today and Tomorrow (US)
-
Multi Specialty Impact of COVID 19 Gastroenterology (US)
-
The Business of Gastroenterology (US)
-
Fellows and Residents (US)
Service Info
Special Topix™ is an independent service that includes access to a report or series of reports based on current events or topics of interest in specialty markets covered by Spherix.
Methodology: Insights are based on data collected from an online survey of respondents recruited from the Spherix Network, a proprietary group of specialty physicians in clinical practice meeting quality screening criteria.
Sample Size and Frequency
Report cadence and deliverable depend upon current event/topic being evaluated.